Barcode Nanotech

Executive Summary

Barcode Nanotech is an Israeli preclinical-stage biotechnology company pioneering a novel lipid-based nanoparticle (LNP) platform for the targeted delivery of RNA and DNA therapeutics. The company's core technology leverages an in-vivo mass-screening platform that uses molecular barcoding combined with AI analytics to identify LNP formulations capable of precise, tissue-specific delivery. This approach addresses a critical bottleneck in nucleic acid therapeutics—off-target effects and limited extrahepatic delivery—potentially enabling safer and more effective treatments for oncology, metabolic diseases, and vaccines. Founded in 2017 and employing 50–200 staff, Barcode Nanotech is privately held with no disclosed funding or valuation; its preclinical stage and the novelty of its platform make it a high-risk, high-reward opportunity in the rapidly evolving LNP space. Barcode Nanotech's platform has the potential to differentiate from established LNP players by enabling delivery beyond the liver, a key hurdle for many RNA therapies. The company's focus spans multiple high-value indications, including oncology and vaccines, where targeted delivery can significantly improve therapeutic indices. While still preclinical, the use of high-throughput barcoding and AI de-risks formulation development and could accelerate path to clinic. Near-term catalysts include lead candidate selection and initial in-vivo proof-of-concept data. The company's success depends on achieving reproducible tissue-specific delivery and forming strategic partnerships to fund IND-enabling studies. Given the competitive landscape and early stage, conviction is moderate but supported by the platform's technological merit.

Upcoming Catalysts (preview)

• Q3 2026Lead Candidate Selection for Oncology Program70% success
• Q4 2026Partnership or Collaboration with Major Pharma for Vaccine Delivery50% success
• H1 2027Completion of GLP Toxicology Studies for Lead Candidate60% success